السبت 6 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) | Novartis | Ongoing | Deferasirox / Defearisox new formula | 2 | CICL670F2201 | King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters | Bayer | Completed | Visanne | 4 | VS1101 | King Khalid University Hospital (Riyadh), Soliman Fakeeh Hospital (Jeddah) |
| A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin | Novonordisk | Completed | BIAsp 30 / Metformin | 4 | BIAsp 3968 | King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada) |
| An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting | MSD | Completed | Sitagliptin | 4 | MK0431-263 | Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh) |
| A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) | Roche | Completed | Pegasys | 4 | MV22009 | King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj) |
| A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan | Novartis | Completed | Vildagliptin / Sulphonylurea / Metformin | 4 | CLAF237A-MAX-AE-02 | Soliman Fakeeh Hospital (Jeddah) |
| A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. | Novartis | Completed | Vildagliptin /Gliclazide / Metformin | 4 | CLAF237A2411 | King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh) |
| UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) | Novartis | Completed | Ranibizumab | 4 | CRFB0021 | King Khaled Eye Specialist Hospital (Riyadh) |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk | Boehringer Ingelheim | Completed | BI 10773 | 3 | 1245.25 | King Fahad Medical City (Riyadh) |
| Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma | Roche | Completed | Bevacizumab | 3 | MO22923 | King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.